Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » Acquired Thrombocytopenias

Abstract Number: PB0821

A Multicenter Double-blind, Double-dummy, Randomized Study of rhTPO vs Eltrombopag in the Treatment of Chinese Immune Thrombocytopenia

H. Mei¹, M. Xu¹, G. Yuan², F. Zhu³, J. Guo⁴, R. Huang⁵, J. Qin⁶, T. Lv², F. Qin³, H. Cai⁴, P. Yin⁷, T. Qin⁷, Y. Hu¹

Abstract Number: PB0820

Altered Hemostatic Potential in Adults with Primary ITP

T. Schramm¹, J. Machacek¹, M. Fillitz², B. Dixer², D. Mehic¹, S. Koder¹, C. Ay¹, I. Pabinger¹, J. Gebhart¹

Abstract Number: PB0828

Autoimmune Platelet Function Disorders: Systematic Review of Acquired Glanzmann Thrombasthenia and Acquired Delta Storage Pool Disease Cases

A. Ferretti¹, M. Bacci², M. Marchetti³, M.A. Alberelli¹, A. Falanga⁴, C. Lodigiani⁵, E. De Candia⁶

Abstract Number: PO155

Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and Practical Recommendations

W.E.M. van Dijk¹, R.J.J. van Es¹, M.E.P. Correa², R.E.G. Schutgens¹, K.P.M. van Galen¹

Abstract Number: PB0832

Drug Induced Purpura in Autologous Hematopoietic Stem Cell Transplantation – A Case Report

T. Quaresma¹, A. Rodrigues¹, A. Garção¹, C. Malcata², A. Silva Martins³, A. Cristina Alho³, M. Galvão¹

Abstract Number: OC 72.4

Durability of Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-hoc Results from the Phase 3 Core and Open-label Extension Study

S. Jain¹, M. Wojdyla², C. Bernheisel², S. Kolodny², M. Vredenburg², T. Gernsheimer³

Abstract Number: PB0830

Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia: ADVANCE SC, a Global Phase 3 Clinical Trial in Progress

C. Broome¹, V. McDonald², S. Jain³, S. Babu⁴, E. Oliva⁵, W. Parys⁶, A. Hultberg⁶, K. De Beuf⁶, D. Gandini⁶, Y. Miyakawa⁷, W. Ghanima⁸

Abstract Number: PB0816

Exploring the Immune-related Biomarkers for Predicting the Efficacy of Rituximab Treatment in Patients with Chronic Immune Thrombocytopenia

X. Wang^1,2,3, H. Li^1,2,3, X. Liu¹, F. Xue¹, W. Liu¹, Y. Chen¹, R. Fu¹, L. Zhang^1,2,3, R. Yang^1,2,3

Abstract Number: PB0827

Fatigue in Chronic Immune Thrombocytopenia Patients: Validation of the Checklist Individual Strength and Comparison to Other Chronically Ill Populations

W.E.M. van Dijk¹, I.A.R. Kuijlaars¹, M.H. Suijker², K.P.M. van Galen¹, R.E.G. Schutgens¹

Abstract Number: PB0834

Idiopathic Thrombocytopenic Purpura: Conventional Prednisolone vs High-dose Dexamethasone

C. Lewis^1,2, Z. Ng^1,3, C. Grove^1,2,3

Abstract Number: PB0825

Immature Platelet Fraction in Systemic Lupus Erythematosus-Related Thrombocytopenia: Potential Predictor of Platelet Response to Treatment?

T. Nguyen¹, D. Truong-Pham¹, T. Huynh¹, T. Nguyen¹, T. Tran¹, L. Phan-Nguyen¹, G. Nguyen-Tran¹, T. Tran¹

Abstract Number: PB0819

Length of Thrombopoietin Receptor Agonist (TPO-RA) Treatment and Persistence in Immune Thrombocytopenia (ITP): Real World United States Claims Analyses

M. Vredenburg¹, S. Kolodny¹, M. Wojdyla¹, H. Boyer¹, T. Darden¹

Abstract Number: PB0826

Off-label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature

M. Capecchi¹, F. Serpenti², J. Giannotta³, L. Pettine⁴, G. Reda⁴, W. Barcellini⁴, B. Fattizzo⁵, I. Martinelli⁶, A. Artoni⁶, F. Peyvandi⁷

Abstract Number: OC 72.2

Phase I/II Ongoing Study of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Immune Thrombocytopenia: Extended Follow-up and Long-term Analyses with Optimal Dose

D.J. Kuter¹, N. Tzvetkov², M. Efraim³, Z. Kaplan⁴, J. Mayer⁵, P. Choi⁶, A.J.G. Jansen⁷, V. McDonald⁸, R. Baker⁹, R. Bird¹⁰, M. Garg¹¹, J. Gumulec¹², M. Kostal¹³, T. Gernsheimer¹⁴, W. Ghanima¹⁵, O. Bandman¹⁶, P. Arora¹⁶, Q. Tran¹⁶, H. Guo¹⁷, N. Cooper¹⁸

Abstract Number: PB0822

Platelet Activation and Function in Adult Patients with Primary Immune Thrombocytopenia

J. Machacek¹, L. Buresch¹, D. Mehic¹, T. Schramm¹, M. Fillitz², B. Dixer², T. Flasch¹, T. Anderle¹, A. Rath¹, C. Ay¹, I. Pabinger¹, J. Gebhart¹

Abstract Number: PB0817

Platelet Apoptosis and Autophagy in Pediatric Immune Thrombocytopenia: New Mechanistic Insights

T. Stein¹, R. Hinselmann¹, C. Gowin¹, D. Greber¹, S. Shllaku¹, N. Gölz¹, M. Schmugge¹, F.D. Franzoso¹

Abstract Number: PB0831

Prevalence of Thrombotic Events and Risk Factors in Patients with Primary Immune Thrombocytopenia

A. Doblas-Marquez¹, F.-J. Lopez-Jaime¹, S. Martin-Tellez¹, I. Sanchez-Bazan¹, M.-I. Muñoz-Perez¹

Abstract Number: PB0824

Refractory Immune Thrombocytopenia (ITP): The Combination of Thrombopoietin Analogs and Immunosuppressants, Experience in a Single Spanish Center

I. Sánchez Bazán¹, S. Martín Téllez¹, F.J. López Jaime¹, M.I. Muñoz¹

Abstract Number: PO157

Self-Administration of Romiplostim in Patients with Chronic Immune Thrombocytopenia Compared with Administration by a Healthcare Provider: A Single Center Experience

F.J. López Jaime¹, A. Doblas Márquez¹, E. Calavia Aranda¹, I. Sánchez Bazán¹, A. Montaño Brioso¹

Abstract Number: PB0835

Serum Complement Levels in Immune Thrombocytopenia: Relation with Clinical Presentation and Treatment Response

S. Pérez -León¹, B. Galmés¹, G. Puguet¹, A. Gutiérrez¹, J.M. Sánchez-Raga¹, M. Canaro-Hyrnik¹